Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

PURPOSE: To assess the efficacy and safety of panzyga® (intravenous immunoglobulin 10%) in preventing serious bacterial infections (SBIs) in patients with primary immunodeficiency diseases (PIDs), a prospective, open-label, multicenter, phase 3 study and an open-label extension study were undertaken...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Immunol
Main Authors: Borte, Michael, Melamed, Isaac R., Pulka, Grazyna, Pyringer, Barbara, Knutsen, Alan P., Ochs, Hans D., Kobayashi, Roger H., Kobayashi, Ai Lan, Gupta, Sudhir, Strach, Magdalena, Smits, William, Pituch-Noworolska, Anna, Moy, James N.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5554470/
https://ncbi.nlm.nih.gov/pubmed/28755067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-017-0424-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados